Douglas J. Manion
Douglas J. Manion M.D. FRCP(C) (born June 2, 1960) is a Canadian board-certified internal medicine doctor. He also holds a Bachelor of Science in Civil Engineering.[1]
Early life and education
Manion was born in Ottawa, Ontario on June 2, 1960. His father John Manion is a Canadian civil servant. At the request of his parents, he studied mathematics and physics in French.[2] In 1979, he began attending the University of Ottawa to receive a Bachelor of Science in Civil Engineering, inspired by a mentor who was designing low-cost sewage systems for Africa.[2] While in school, he became aware of an epidemic in Africa and began considering pre-med classes.[3] In 1983, during his final year of engineering school, Manion began taking pre-med courses. In 1990, he graduated from University of Ottawa with a medical degree in Internal medicine.[1][2] From 1992 to 1997, he completed a postdoctoral fellowship at Harvard Medical School / Massachusetts General Hospital where he performed retrovirology research.[2][4]
Career
From 1997 to 2001, Manion worked as a medical director for DuPont Pharmaceuticals.[1] While there, he led clinical research[5] for Efavirenz (brand name Sustiva), one of the first major HIV/AIDS medicines. Then, from 2001 to 2005, he worked for GlaxoSmithKline, where he was the VP of Clinical Development and Medical Affairs for HIV.[1] Beginning in 2005, he was the VP of Clinical Research for Virology, Immunology, and Neurology at Bristol Myers Squibb.[1] In 2010, he was promoted to SVP of Virology Development in Japan, then the SVP Head of Global Pharmacovigilance and Epidemiology in mid-2014, and finally the SVP Head of Specialty Development in late 2014.[1] While working for Bristol Myers Squibb, he worked on BMS' effort to cure Hepatitis C virus. In an interview, he referred to this work as "...a Manhattan Project in the world in terms of curing [Hepatitis C virus]".[4] In 2017, Manion joined Kleo Pharmaceuticals as its CEO.[6][7] In July 2021, he joined Arena Pharmaceuticals as EVP of Research and Development.[8]. In December 2021, Arena Pharmaceuticals was acquired by Pfizer for approximately $6.6 billion.[9] Following that, Manion joined Aclaris Therapeutics in August 2022 as President & Chief Operating Officer,[10] transitioning to President & Chief Executive Officer in January 2023.[11] In January 2024, it was announced that Manion would step down from his position and leave the company.[12]
Achievements
Manion is known for his research in HIV that led to the creation of Efavirenz.[5] Through his HIV/AIDS research, he met with people such as NIAID director Anthony Fauci and former CDC director Robert Redfield.[2] At the World AIDS Conference, he first met prominent HIV/AIDS activist Sean Strub,[2] with whom he worked closely through the COVID-19 pandemic.[13]
Non-pharmaceutical
Manion is currently a council member on the Milford, Pennsylvania borough council,[14] having been elected in 2021.[15] He is also on the board of the Milford Water Authority.[16] In 2020, along with mayor Sean Strub, he founded the Milford Covid Volunteer Task Force, helping manage the borough's response to the COVID-19 pandemic.[13]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 "Doug Manion - Milford, Pennsylvania, United States | Professional Profile | LinkedIn". www.linkedin.com. Retrieved 2024-03-01.[unreliable source?]
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 Cohen, Jessica. "Empathy for underdogs inspired epidemiologist". Times Herald-Record. Retrieved 2022-06-15.
- ↑ Zehr, Leonard (2020-04-07). "Dr. Doug Manion of Kleo Pharmaceuticals talks up new approach to treating multiple myeloma". BioTuesdays. Retrieved 2024-03-01.
- ↑ 4.0 4.1 Ononye-Onyia, Dr. Sophia (December 3, 2020). "Amplifying Scientific Innovation: Dr Doug Manion, CEO Kleo Pharma".
- ↑ 5.0 5.1 Staszewski, Schlomo; Morales-Ramirez, Javier; Tashima, Karen T.; Rachlis, Anita; Skiest, Daniel; Stanford, James; Stryker, Richard; Johnson, Philip; Labriola, Dominic F.; Farina, Dianne; Manion, Douglas J. (1999-12-16). "Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults". New England Journal of Medicine. 341 (25): 1865–1873. doi:10.1056/NEJM199912163412501. ISSN 0028-4793. PMID 10601505.
- ↑ "Manion Named Chief Executive Officer at Kleo Pharmaceuticals. - Free Online Library". www.thefreelibrary.com. Retrieved 2022-06-16.
- ↑ "Kleo Pharmaceuticals Inc. Appoints Douglas J. Manion M.D. as Chief Executive Officer". www.prnewswire.com (Press release). Retrieved 2024-03-01.
- ↑ "Arena Pharmaceuticals Appoints Doug Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development". www.businesswire.com. 2021-07-19. Retrieved 2022-06-16.
- ↑ "Pfizer concludes Arena Pharmaceuticals acquisition for $6.7bn". Pharmaceutical Technology. 2022-03-14. Retrieved 2022-06-16.
- ↑ "Aclaris Therapeutics Expands Leadership Team". Yahoo Finance. 2022-08-01. Retrieved 2024-03-12.
- ↑ "Aclaris Therapeutics Announces Key Leadership Transitions". Yahoo Finance. 2022-11-22. Retrieved 2024-03-12.
- ↑ "Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review". Yahoo Finance. 2024-01-16. Retrieved 2024-03-12.
- ↑ 13.0 13.1 Rosenthal, Marilyn. "Dr. Manion says there's a 'whole lot' Pike County can do to keep pandemic from getting worse". www.pikecountycourier.com. Retrieved 2024-03-01.
- ↑ "Milford, Pennsylvania Borough Council". Borough of Milford. Retrieved 2024-03-01.
- ↑ "Election results: Upset in Dingman, most other incumbents returned to office". www.pikecountycourier.com. Retrieved 2024-03-01.
- ↑ "Board Members – Milford Water Authority". milfordpawater.com. Retrieved 2024-03-01.
This article "Douglas J. Manion" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Douglas J. Manion. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
